Jonathan Young, Chief Operating Officer at Akero Therapeutics, Inc. (AKRO), sold 100,000 shares at $44.17 ($4.5M) on 2025-03-04, disclosed to the SEC on 2025-03-05.
Scheduled sale ($4.5M) by Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.17 | 11,447 | $506K | 11.3% |
| 2 | $44.17 | 11,447 | $506K | 11.3% |
| 3 | $45.07 | 38,553 | $1.7M | 38.7% |
| 4 | $45.07 | 38,553 | $1.7M | 38.7% |
| Total | $44.86 avg | 100,000 | $4.5M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-04 | $705K | — | Filing → |
| AKRO | SELL | 2025-08-13 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $159K | — | Filing → |